![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Prediction accuracy of the NASHmap
algorithm designed to screen for presence of NASH
|
|
|
AASLD 2020 Nov 11-16
Reported by Jules Levin
Lynda C. Doward,1 James Twiss,1 Diane Whalley,1 Maria-Magdalena Balp,2 Clifford Brass,3 Juergen Loeffler,2 Donna R Cryer,4 Jennifer Cai,3 Patricia Lopez,2 Eric J. Lawitz,5Quentin M. Anstee*6, Dr. Arun Sanyal*71RTI Health Solutions, Manchester, United Kingdom; 2Novartis Pharma AG, Basel, Switzerland; 3Novartis Pharmaceuticals Corp., East Hanover, NJ, USA ; 4Global Liver Institute; 5Texas Liver Institute; 6Newcastle University, Newcastle-upon-Tyne, United Kingdom; 7Virginia Commonwealth University Medical Center; *Joint Senior Authors
All too often PLWH may not be evaluated for fatty liver. NAFLD is not on the radar much in HIV. You can start a discussion with your doctor about this topic. Fatty liver, NAFLD, NASH has been reported in higher prevalence among HIV+, it is an aging comorbidity that needs more attention & evaluation. Jules
![1201201](../images/120120/120120-2/1201201.gif)
![1201202](../images/120120/120120-2/1201202.gif)
![1201203](../images/120120/120120-2/1201203.gif)
![1201204](../images/120120/120120-2/1201204.gif)
![1201205](../images/120120/120120-2/1201205.gif)
![1201206](../images/120120/120120-2/1201206.gif)
![1201207](../images/120120/120120-2/1201207.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|